HIV TREATMENT
2020
Pharmaceutical companies, SRAs, WHO Prequalification Programme (PQ) and NRAs commit to:
Action 27. Mobilize their networks and work with communities to help build treatment literacy, generate demand, and expand access to ARVs among children.
Action 34. Increase efforts to share information on the roll-out of new paediatric formulations, including lessons learned.
Paediatric HIV & TB : Rome Action Plan
Merck & Co, Inc.
Merck & Co., Inc., is committed to make pediatric Raltegravir available at no profit in low income, least developed countries and across Sub-saharan African countries until generics are available.
Committed by:
Merck & Co, Inc
Sub-Actions & Milestones
Sub-action Merck.1
Merck & Co., Inc., is committed to make pediatric Raltegravir available at no profit in low income, least developed countries and across Sub-saharan African countries until generics are available.
-
Merck & Co., Inc., confirmed (in a meeting with PEPFAR) their intention to provide paediatric drugs at access pricing until generics are available, and potentially beyond in LMIC.
-
Milestone Merck.1.1
-
-
-
-
Document (s)
-
-
-
-
Updates
Notes
Responsible